US4746729A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Cartilage-derived leukocyte elastase-inhibitor
Assignee: RUSH-PRESBYTERIAN-ST LUKE'S MEDICAL CENTER 1653 WEST CONGRESS PARKWAY CHICAGO ILLINOIS 60612 A NOT-FOR-PROFIT CORP OF ILLINOIS
•
Filing: 1986-07-30
•
Granted: 1988-05-24
•
Expires: 2006-07-30
Abstract
Abstract A protein or a pharmaceutically acceptable salt thereof. The protein has a molecular weight of 10,000-30,000 Dalton, an isoelectric point greater than 9.5, and an N terminus of the sequence H-Lys-X-Phe-Lys-Val-Asp-Val-Leu-Ala-Ala-Leu-X-Phe-Asn-Ala-, wherein X is an amino acid or a tryptic cleavage product which has the sequence -Gly-Ala-Asn-Ala-Val-Asn-. Methods for the isolation and purification of the protein, compositions containing the protein, and methods for the use of the protein and compositions, are also disclosed.
Inventors
- 👤 Klaus E. Kuettner
- 👤 Dominique Tripier
- 👤 Dietrich Brocks
- 👤 Michael T. DiMuzio
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 13:44
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/81; C07K14/8107; C07K14/811; C07K7/00; C07K7/04; C07K7/08; A; A61; A61P; A61P11/00; A61P13/00; A61P13/02; A61P15/00; A61P17/00; A61P29/00; A61P35/00; A61P35/02; A61P7/00; A61P7/02; A61P9/00; A61P9/10; B; B24; B24B; B24B53/00; A61K; A61K38/00; Y; Y10; Y10S; Y10S530/00; Y10S530/827; Y10S530/84
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
61 words
A substantially purfied protein or a pharmaceutically acceptable salt thereof, said protein having a molecular weight of 10,000-30,000 Dalton, an isoelectric point greater than 9.5, and an aminoterminal amino acid sequence of ##STR4## wherein each X may be identical or different and each denotes a naturally occurring amino acid or a tryptic cleavage product that has the amino acid sequence -Gly-Ala-Asn-Ala-Val-Asn-.
Claim 2
Dependent Claim
61 words
A substantially purfied protein or a pharmaceutically acceptable salt thereof, said protein having a molecular weight of 10,000-30,000 Dalton, an isoelectric point greater than 9.5, and an aminoterminal amino acid sequence of ##STR4## wherein each X may be identical or different and each denotes a naturally occurring amino acid or a tryptic cleavage product that has the amino acid sequence -Gly-Ala-Asn-Ala-Val-Asn-.
Claim 3
Dependent Claim
21 words
A protein or a pharmaceutically acceptable salt thereof as claimed in claim 1, which has a molecular weight of 12,000-20,000 Dalton.
Claim 4
Dependent Claim
21 words
A protein or a pharmaceutically acceptable salt thereof as claimed in claim 1, which has a molecular weight of 14,000-18,000 Dalton.
Claim 5
Dependent Claim
22 words
A protein or a pharmaceutically acceptable salt thereof as claimed in claim 1, which has a molecular weight of approximately 15,000 Dalton.
Claim 6
Dependent Claim
30 words
A protein or a pharmaceutically acceptable salt thereof as claimed in claim 1, wherein the radical X is selected from the group consisting of Ser, Thr, Glu, Asn, and Cys.
Claim 7
Dependent Claim
18 words
A protein or a pharmaceutically acceptable salt thereof as claimed in claim 5, in which X denotes Ser.
Claim 8
Dependent Claim
24 words
A protein or a pharmaceutically acceptable salt thereof as claimed in claim 5, in which either or both of the radicals X are glycosylated.
Claim 9
Dependent Claim
82 words
A protein or a pharmaceutically acceptable salt thereof as claimed in claim 1, the amino acid analysis of which is: ______________________________________
Cys 6.8 ± 15%
Asp 16.8 ± 15%
Thr 7.6 ± 15%
Ser 5.8 ± 15%
Glu 10.4 ± 15%
Gly 7.8 ± 15%
Ala 10.4 ± 15%
Val 4.1 ± 15%
Met 1.0 ± 15%
Ile 2.0 ± 15%
Leu 12.2 ± 15%
Tyr 3.8 ± 15%
Phe 5.0 ± 15%
Lys 37.4 ± 15%
Arg 16.6 ± 15%
______________________________________
Claim 10
Dependent Claim
82 words
A protein or a pharmaceutically accepatable salt thereof as claimed in claim 1, the amino acid analysis of which is: ______________________________________
Cys 6.8 ± 10%
Asp 16.8 ± 10%
Thr 7.6 ± 10%
Ser 5.8 ± 10%
Glu 10.4 ± 10%
Gly 7.8 ± 10%
Ala 10.4 ± 10%
Val 4.1 ± 10%
Met 1.0 ± 10%
Ile 2.0 ± 10%
Leu 12.2 ± 10%
Tyr 3.8 ± 10%
Phe 5.0 ± 10%
Lys 37.4 ± 10%
Arg 16.6 ± 10%
______________________________________
Claim 11
Dependent Claim
26 words
A pharmaceutical composition comprising an effective amount of a protein or a pharmaceutically acceptable salt thereof as claimed in claim 1 and a pharmaceutically acceptable carrier.
Claim 12
Dependent Claim
37 words
A method of inhibiting PMN elastase which comprises the step of adminsitering to a hos in need of such treatment an effective amount of a protein or a pharmaceutically accepatable salt thereof as claimed in claim 1.
Claim 13
Dependent Claim
26 words
An enzymatic peptide cleavage product of a protein or a pharmaceutically acceptable salt thereof as claimed in claim 1 consisting of 6 or more amino acids.
Claim 14
Dependent Claim
53 words
A method of treating pulmonary emphysema, chronic bronchitis, cystic fibrosis, bronchiectasis, adult respiratory distress syndrome, atherosclerosis, arthritis, psoriasis, vasculitis, glomerulonephritis, consumption coagulopathies associated with gram-negative sepsis, and leukemias, compring the step of administering to an affected host an effective amount of a protein or pharmaceutically acceptable salt thereof as claimed in claim 1.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-05-24 | 1991-11-23 | 1992-05-24 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-05-24 | 1995-11-23 | 1996-05-24 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-05-24 | 1999-11-23 | 2000-05-24 | $7700.00 | Window Closed / Lapsed |